Efficacy and safety of low-dose rituximab as induction therapy for antineutrophil cytoplasmic antibody-associated vasculitis with renal involvement: a Chinese case series

BACKGROUND: Rituximab (RTX) is a standard therapy for antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). However, the most frequently used dose may lead to severe adverse effects (SAEs). We explored the efficacy and safety of low-dose RTX in Chinese patients with AAV. METHODS: A...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Lin, Lu, Haitao, Zou, Guming, Wang, Haifeng, Li, Jing, Yang, Yue, Zhang, Jian, Wang, Xueling, Li, Wenge, Zhuo, Li
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9906883/
https://www.ncbi.nlm.nih.gov/pubmed/36755215
http://dx.doi.org/10.1186/s12882-023-03075-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9906883/
https://www.ncbi.nlm.nih.gov/pubmed/36755215
http://dx.doi.org/10.1186/s12882-023-03075-8

Ejemplares similares